Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/01/30 05:16:52」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

English Journal

  • Medicaid coverage of medications to treat alcohol and opioid dependence.
  • Mark TL1, Lubran R2, McCance-Katz EF3, Chalk M4, Richardson J5.
  • Journal of substance abuse treatment.J Subst Abuse Treat.2015 Aug;55:1-5. doi: 10.1016/j.jsat.2015.04.009. Epub 2015 Apr 16.
  • Substance use disorders affect 12% of Medicaid beneficiaries. The prescription drug epidemic and growing need for treatment of alcohol and opioid dependence have refocused states' attention on their provision of substance use disorder treatment services, including medications. This study characteriz
  • PMID 25921475
  • Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.
  • Jones JD1, Sullivan MA1, Vosburg SK1, Manubay JM1, Mogali S1, Metz V1, Comer SD1.
  • Addiction biology.Addict Biol.2015 Jul;20(4):784-98. doi: 10.1111/adb.12163. Epub 2014 Jul 25.
  • In spite of the clinical utility of buprenorphine, parenteral abuse of this medication has been reported in several laboratory investigations and in the real world. Studies have demonstrated lower abuse liability of the buprenorphine/naloxone combination relative to buprenorphine alone. However, cli
  • PMID 25060839
  • Effectiveness and Safety of Transdermal Buprenorphine Versus Sustained-release Tramadol in Patients With Moderate to Severe Musculoskeletal Pain: An 8-Week, Randomized, Double-Blind, Double-Dummy, Multicenter, Active-controlled, Noninferiority Study.
  • Leng X1, Li Z, Lv H, Zheng Y, Liu Y, Dai K, Yao C, Yan X, Zeng X.
  • The Clinical journal of pain.Clin J Pain.2015 Jul;31(7):612-20. doi: 10.1097/AJP.0000000000000144.
  • OBJECTIVES: The aim of this noninferiority study was to investigate clinical effectiveness and safety of buprenorphine transdermal system (BTDS) in patients with moderate to severe musculoskeletal pain inadequately controlled with nonsteroidal anti-inflammatory drugs, compared with sustained-release
  • PMID 25503600

Japanese Journal

  • 経験と考察 変形性関節症および腰痛症に対するブプレノルフィン経皮吸収型製剤の使用経験
  • 運動器慢性疼痛に対するブプレノルフィン貼付剤の短期治療成績 : 多施設共同前向き研究
  • Journal of musculoskeletal pain research = 日本運動器疼痛学会誌 7(1), 32-36, 2015
  • NAID 40020467408
  • Effect of buprenorphine on genotoxicity evaluation of chemicals by the rat liver micronucleus test with partial hepatectomy

Related Links

Medical uses [edit] Its primary uses in medicine are in the treatment of those addicted to opioids, such as heroin and oxycodone, but it may also be used to treat pain, and someti
Buprenorphine or buprenorphine and naloxone may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: headache stomach pain constipation vomiting difficulty falling asleep or ...




drug abuse, substance abuse


  • 濫用 substance abuse:a pattern of abnormal substance use that leads to impairment of occupational, physical, or social functioning(BBS.73)
  • 依存 substance dependence:ub stance abuse puls withdrawal symptoms, tolerance, or a pattern of repetitive use(BBS.73)
  • 離脱 withdrawal:the development of physical or pschological symptoms after the reduction or cessation of intake of a substance(BBS.73)
  • 耐性 tolerance:the need for increased amounts of the substance to achieve the same positive psychological effect(BBS.73)
  • 交差耐性 cross-tolerance:the development of tolerance to one substance as the result of using another substance(BBS.73)


  • コカイン cocaine crack freebase 精神依存有り。身体依存無し 精神依存生じやすい。耐性発現殆ど無し コカ


  精神依存 身体依存






  • モルフィンと多くのμ,κアゴニストは瞳孔の縮小を引き起こす。これは瞳孔を支配する副交感神経の興奮による。μアゴニストを中毒量投与すると縮瞳し、pinpoints pupupilsはpathognomonicである。(GOO.559)


μ受容体 δ受容体 κ受容体
morphine +++  
methadone +++    
etorphine +++ +++ +++
levorphanol +++    
fentanyl +++    
sufentanil +++
DAMGO +++    
butorphanol P   +++
buprenorphine P   ーー
naloxone ーーー ーー
naltrexone ーーー ーーー
CTOP ーーー    
diprenorphine ーーー ーー ーーー
β-funaltrexamine ーーー ++
naloxonazine ーーー
nalorphine ーーー  
pentazocine P   ++
nalbuphine ーー   ++
naloxone benzoylhydrazone ーーー
bremazocine +++ ++ +++
ethylketocyclazocine P +++
U50,488     +++
U69,593     +++
spiradoline   +++
nor-Binaltorphimine ーーー
naltrindole ーーー
DPDPE   ++  
[[[[D-Ala2,Glu4]deltorphin]]   ++  
DSLET ++  
endogenous Peptides      
met-enkephalin ++ +++  
leu-enkephalin ++ +++  
β-endorphin +++ +++  
dynorphin A ++   +++
dynorphin B +++
α-neoendorphin +++
+アゴニスト ーアンタゴニスト P partial agonist


         μ受容体 κ受容体
レミフェンタニル +++  ー
フェンタニル   +++  -
モルヒネ     +++  +
ペチジン     ++   +
トラマドール   +    -
ペンタゾシン   ー    ++
ブプレノルフィン P    ー
ナロキソン    ー    -



塩酸ブプレノルフィン buprenorphine hydrochloride
レペタン Lepetan